In 2003, there seemed to be good reasons to leave weight-loss drugs out of the benefit, write Inmaculada Hernandez of the University of California, San Diego, and coauthors in their September 2023 editorial in the Journal of General Internal Medicine, Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform. When members of Congress worked on the Part D benefit, the drugs available on the market were known to have limited effectiveness and unpleasant side effects
Novo Nordisk has reported they have run out of stock of Wegovy 1.7mg for the month of December and anticipate possible disruptions of related GLP-1 liraglutide supply8
Can L-Tartrate cause any side effects
Classification of drug-induced liver injury (DILI) Intrinsic DILI Certain drugs and chemicals have inherent liver toxicity, causing a predictable spectrum of liver damage that worsens with increase in dose or exposure [3]
Sustainability and Long-Term Effects: With GLP-1 medications, many users need to continue long-term use to maintain weight loss
